LDL aggregation - A novel biomarker That predicts mortality risk in Heart Disease Medha Baranwal Baranwal20 July 2018 7:28 PM ISTA new study published in the European Heart Journal shows that the presence of sticky, aggregation-prone low-density lipoprotein (LDL) in circulation...
Dapagliflozin reduces hospitalisation rate and death risk in heart failure: DECLARE Trial Medha Baranwal Baranwal21 March 2019 7:25 PM ISTDELHI: Diabetes drug dapagliflozin offers cardiovascular benefits that extend across a wide spectrum of patients with heart failure, and also reduces...
FDA approves new drug for osteoporosis in women with high fracture risk Hina Zahid9 April 2019 7:28 PM ISTFDA has approved a new drug for osteoporosis in women with high fracture risk.The U.S. Food and Drug Administration has approved Evenity...
SGLT2 inhibitors and Atrasentan- New options to slow CKD progression in Diabetes Dr. Kartikeya2 May 2019 7:02 PM ISTSodium-glucose transport inhibitors (SGLT2 inhibitors) and Atrasentan are two new and emerging treatment options to slow Chronic kidney disease (CKD)...
PCSK9 inhibitor Evolocumab safely cuts LDL cholesterol across all stages of CKD Deepanjana Sarkar17 Jun 2019 8:20 PM ISTPCSK9 inhibitor, Evolocumab is clinically effective and safe for lowering Low-density lipoprotein cholesterol, LDL cholesterol levels across all...
Empagliflozin gets FDA Fast-Track status for Chronic Heart Failure Treatment Deepanjana Sarkar28 Jun 2019 7:30 PM ISTThe U.S Food and Drug Administration has tagged sodium-glucose co-transporter 2 (SGLT2) inhibitor Empagliflozin with Fast-Tracked designation for the...
Sacubitril/valsartan combo effective option in Heart Failure of any etiology: JACC Deepanjana Sarkar14 July 2019 8:28 PM ISTHeart failure therapy has become complicated due to varying etiology that affects the treatment outcomes. A new study published in the Journal of...
Dapagliflozin receives FDA fast track designation for chronic kidney disease Medha Baranwal Baranwal29 Aug 2019 7:10 PM ISTAstraZeneca’s dapagliflozin (FARXIGA) has received FDA's Fast Track designation for chronic kidney disease (CKD). Dapagliflozin is a sodium-glucose...
Sedentary lifestyle for 20 years may double mortality risks: ESC 2019 update Deepanjana Sarkar31 Aug 2019 3:45 PM ISTSedentary lifestyle for 20 years may double mortality risk as compared to being physically active, revealed results from the HUNT study presented at...
COMPLETE revascularization bests culprit only PCI at reducing death risk and MI recurrence: ESC 2019 Update Medha Baranwal Baranwal1 Sept 2019 8:10 PM ISTCOMPLETE revascularization bests culprit only Percutaneous Coronary Intervention (PCI) at reducing death risk and MI recurrence is a new ESC 2019...
Individuals with prior history of malaria may have increased risk of Heart Failure: ESC 2019 Update Deepanjana Sarkar2 Sept 2019 7:25 PM ISTIndividuals with a prior history of malaria may have an increased risk of heart failure. according to a small study presented today at European...
Guidelines on acute pulmonary embolism by European Society of Cardiology: ESC 2019 update Hina Zahid4 Sept 2019 7:00 PM ISTGuidelines on acute pulmonary embolism have been released by the European Society of Cardiology. They were developed in collaboration with the...
